Bifogade filer
Kurs
+16,69%
Prenumeration
Kalender
Est. tid* | ||
2026-02-19 | 07:30 | Bokslutskommuniké 2025 |
2025-11-13 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-05-16 | N/A | X-dag ordinarie utdelning SUS 0.00 SEK |
2025-05-15 | N/A | Årsstämma |
2025-05-14 | 07:30 | Kvartalsrapport 2025-Q1 |
2025-02-19 | - | Bokslutskommuniké 2024 |
2024-11-14 | - | Kvartalsrapport 2024-Q3 |
2024-08-22 | - | Kvartalsrapport 2024-Q2 |
2024-05-17 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
2024-05-16 | - | Årsstämma |
2024-05-15 | - | Kvartalsrapport 2024-Q1 |
2024-02-21 | - | Bokslutskommuniké 2023 |
2023-11-09 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-19 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
2023-05-17 | - | Årsstämma |
2023-05-16 | - | Kvartalsrapport 2023-Q1 |
2023-02-22 | - | Bokslutskommuniké 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-05-13 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
2022-05-12 | - | Årsstämma |
2022-05-11 | - | Kvartalsrapport 2022-Q1 |
2022-02-16 | - | Bokslutskommuniké 2021 |
2021-11-10 | - | Kvartalsrapport 2021-Q3 |
2021-08-20 | - | Kvartalsrapport 2021-Q2 |
2021-08-16 | - | Extra Bolagsstämma 2021 |
2021-05-14 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
2021-05-12 | - | Årsstämma |
2021-05-11 | - | Kvartalsrapport 2021-Q1 |
2021-02-11 | - | Bokslutskommuniké 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-05-25 | - | Split SUS 1:5 |
2020-05-07 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
2020-05-06 | - | Årsstämma |
2020-05-05 | - | Kvartalsrapport 2020-Q1 |
2020-02-07 | - | Bokslutskommuniké 2019 |
2019-11-07 | - | Kvartalsrapport 2019-Q3 |
2019-08-23 | - | Kvartalsrapport 2019-Q2 |
2019-07-17 | - | Extra Bolagsstämma 2019 |
2019-05-10 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
2019-05-09 | - | Årsstämma |
2019-05-08 | - | Kvartalsrapport 2019-Q1 |
2019-02-22 | - | Bokslutskommuniké 2018 |
2018-11-21 | - | Kvartalsrapport 2018-Q3 |
2018-08-24 | - | Kvartalsrapport 2018-Q2 |
2018-05-23 | - | X-dag ordinarie utdelning SUS 0.00 SEK |
2018-05-22 | - | Årsstämma |
2018-05-22 | - | Kvartalsrapport 2018-Q1 |
2018-02-22 | - | Bokslutskommuniké 2017 |
2017-11-22 | - | Kvartalsrapport 2017-Q3 |
2017-08-17 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Surgical Science has, in its operations in the USA, received an order from a large American hospital chain for USD 6.7 million, corresponding to approximately SEK 65.9 million. The order is for a larger number of products, including simulators for training in endoscopy, laparoscopy and ultrasound.
The forecast is that the products will be delivered, and a majority of the revenues will be recognized, over the next six months.
"It is very gratifying to see one of the leading hospital chains in the United States invest so thoughtfully in increasing patient safety through simulation. We are proud to be able to offer this customer a complete portfolio of simulators for different specialties", says Gisli Hennermark, CEO of Surgical Science.
Gothenburg, Sweden, May 26, 2022
Surgical Science Sweden AB (publ)
The press release, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
For further information, please contact:
Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com
Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com
About Surgical Science Sweden AB (publ)
One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the clinical environment. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.
Surgical Science has more than 200 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Stockholm, Sweden, as well as in Tel Aviv, Israel and Seattle, US. Through sales offices in the US, France and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Phone: +46 8-463 83 00; E-mail: certifiedadviser@penser.se).
This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-26 17:25 CEST.